WAYS TO BATTLE THE $431 BILLION FAKE PHARMACEUTICAL INDUSTRY

Brian Gurney, Gary Amundson and Salem L Boumediene

Review of Business and Finance Studies, 2017, vol. 8, issue 1, 33-40

Abstract: Nowadays, counterfeit drugs are available in the marketplace more than ever. One has no idea whether they are acquiring the genuine drug or not. Many deaths have occurred because of mistakes made by consuming counterfeit medication. Not only does it alter one’s health but it also crushes their hopes. The data concerning counterfeit drugs are increasingly being published in reports and reviews. It seems like government does not care about the issue since it is ongoing and growing. Governments seem to underestimate the importance of the issue, hence its growing prospect. Harsher sanctions are needed to prove that counterfeiting is not an unpunished crime. Whoever commits that felony has to face the consequences that come along with breaking the law and possibly participating in harming and endangering one’s life

Keywords: Medicine; Counterfeit Drugs; Generic; Regulation (search for similar items in EconPapers)
JEL-codes: F19 F23 I10 I18 I19 K20 K42 (search for similar items in EconPapers)
Date: 2017
References: Add references at CitEc
Citations:

Downloads: (external link)
http://www.theibfr2.com/RePEc/ibf/rbfstu/rbfs-v8n1-2017/RBFS-V8N1-2017-3.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ibf:rbfstu:v:8:y:2017:i:1:p:33-40

Access Statistics for this article

Review of Business and Finance Studies is currently edited by Terrance Jalbert

More articles in Review of Business and Finance Studies from The Institute for Business and Finance Research
Bibliographic data for series maintained by Mercedes Jalbert ( this e-mail address is bad, please contact ).